

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

SEP 14 2009

Application Number	10/528,824
Filing Date	March 23, 2005
First Named Inventor	Alain Rambach
Art Unit	1657
Examiner Name	Herbert J. Lilling
Attorney Docket Number	10618-0004-00

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NONPATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		Oxoid Product Detail: Nutrient Agar Dehydrated Culture Media, pages 1-2, undated.	
		Murray, P.R., et al. (eds.), Manual of Clinical Microbiology, 7 th Edition, "Staphylococcus and Micrococcus," pp. 264-77 (1999).	
		Cavassini, M. et al., "Evaluation of MRSA-Screen, a Simple Anti-PbP 2a Slide Latex Agglutination Kit, for Rapid Detection of Methicillin Resistance in <i>Staphylococcus aureus</i> ," Journal of Clinical Microbiology, Vol. 37, no. 5, May, 1999, pp. 1591-1594.	
		Kobayashi, N., et al., "Detection of <i>mecA</i> , <i>femA</i> , and <i>femB</i> genes in clinical strains of staphylococci using polymerase chain reaction," Epidemiol. Infect., Vol. 113, 1994, pp. 259-266.	
		Merlino, J., et al., "Detection and expression of methicillin/oxacillin resistance in multidrug-resistant and non-multidrug-resistant <i>Staphylococcus aureus</i> in Central Sydney, Australia," Journal of Antimicrobial Chemotherapy, Vol. 49, May, 2002, pp. 793-801.	
		Kosmidis, J., et al., "Cefoxitin, a New Semi-synthetic Cephamycin: An In-vitro and In-vivo Comparison with Cephalothin," British Medical Journal, Vol. 15, December, 1973, pp. 653-655.	
		Kojo, H., et al., "Antibacterial Activity of Ceftizoxime (FK 749), a New Cephalosporin, Against Cephalosporin-Resistant Bacteria, and Its Stability to β -Lactamase," Antimicrobial Agents and Chemotherapy, Vol. 16, No. 5, November, 1979, pp. 549-553.	
		Lang, Selwyn D.R., et al., "Comparison of Cefoperazone, Cefotaxime, and Moxalactam (LY127935) Against Aerobic Gram-Negative Bacilli," Antimicrobial Agents and Chemotherapy, Vol. 17, No. 3, March, 1980, pp. 488-493.	
		Neu, Harold C., et al., "In Vitro Activity and β -Lactamase Stability of a New Difluoro Oxacephem, 6315-S," Antimicrobial Agents and Chemotherapy, Vol. 30, No. 5, November, 1986, pp. 638-644.	
		Public Health Agency of Canada, "Guidelines for the Testing and Reporting of Antimicrobial Susceptibilities of Methicillin Resistant <i>Staphylococcus aureus</i> (MRSA) and Commentary on Methicillin Resistant Coagulase Negative Staphylococci (MR-CNS)," Canadian External Quality Assessment Advisory Group for Antibiotic Resistance, September, 1998.	
		Apfaltar, Petra, et al., "Performance of a new chromogenic oxacillin resistance screen medium (Oxoid) in the detection and presumptive identification of methicillin-resistant <i>Staphylococcus aureus</i> ," Diagnostic Microbiology and Infectious Disease, Vol. 44, (2002), pp. 209-211.	
		Hanaki, Hideaki et al., "TOC-39, a Novel Parenteral Broad-Spectrum Cephalosporin with Excellent Activity against Methicillin-Resistant <i>Staphylococcus aureus</i> ," Antimicrobial Agents and Chemotherapy, Vol. 39, No. 5, May 1995, pp. 1120-1126.	
		Lally, Richard T., "Evaluation of Mannitol Salt Agar with Oxacillin as a Screening Medium for Methicillin-	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/528,824
Filing Date	March 23, 2005
First Named Inventor	Alain Rambach
Art Unit	1657
Examiner Name	Herbert J. Lilling
Attorney Docket Number	10618-0004-00

NONPATENT LITERATURE DOCUMENTS

	Resistant <i>Staphylococcus aureus</i> ," Journal of Clinical Microbiology, Vol. 22, No. 4, Oct. 1985, pp. 501-504.	
	"Evaluation of a New Medium, Oxacillin Resistance Screening Agar Base, for the Detection of Methicillin-Resistant <i>Staphylococcus aureus</i> from Clinical Specimens," Journal of Clinical Microbiology, Vol. 39, No. 9, Sept. 2001, p. 3422.	
	Van Enk, Richard A., et al., "Use of a Primary Isolation Medium for Recovery of Methicillin-Resistant <i>Staphylococcus aureus</i> ," Journal of Clinical Microbiology, Vol. 30, No. 2, Feb. 1992, p. 504-505.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Application Number	10/528,824
Filing Date	March 23, 2005
First Named Inventor	Alain Rambach
Art Unit	1657
Examiner Name	Herbert J. Lilling
Attorney Docket Number	10618.0004

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NONPATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		BD BBL TM CHROMagar TM Staph aureus product leaflet, © 2005.	
		DREW et al., "Reliability of the Kirby-Bauer Disc Diffusion Method for Detecting Methicillin-Resistant Strains of <i>Staphylococcus aureus</i> ," Applied Microbiology, 24(2):240-47 (1972).	
		HIRAMATSU et al., "Molecular Cloning and Nucleotide Sequence Determination of the Regulator Region of <i>mecA</i> Gene in Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA)," FEBS Letters, 298(23):133-136 (1992).	
		JOFFIN et al., Microbiology Technique - Volume 1, Dictionary of Techniques, 3 rd Ed., pp. 16-19, 24, 57-60, 140-147, CRDP d'Aquitaine (2001).	Yes
		JORGENSEN et al., "Performance Standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition; Approved Standard," NCCLS document M2-A6 (ISBN 1-56238-308-6), 17(1) (1997).	
		JORGENSEN et al., "Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Fourth Edition; Approved Standard," NCCLS document M7-A4 (ISBN 1-56239-309-4), 17(2) (1997).	
		MURAKAMI et al., "Increased Susceptibility to Cephamycin-Type Antibiotics of Methicillin-Resistant <i>Staphylococcus aureus</i> Defective in Penicillin-Binding Protein 2," Antimicrobial Agents and Chemotherapy, 31(9):1423-24 (1987).	
		ROWE et al., "Agar Diffusion, Agar Dilution, Etest [®] , and Agar Screening Test in the Detection of Methicillin Resistance in <i>Staphylococci</i> ," Diagnostic Microbiology and Infectious Disease, 43(1):45-48 (2002).	
		SAKOULAS et al., "Methicillin-Resistant <i>Staphylococcus aureus</i> : Comparison of Susceptibility Testing Methods and Analysis of <i>mecA</i> -Positive Susceptible Strains," Journal of Clinical Microbiology, 39(11):3946-51 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.